About AntibodySystem
Founded in 2019, AntibodySystem develops research bioreagents for life science and biomedical applications. Its expertise spans recombinant antibodies, recombinant proteins, biosimilars and research-use ELISA kits. The company designs reagents that support accurate target detection, protein characterisation and assay development. Its technologies enable researchers to investigate immune responses, therapeutic targets and infectious diseases. Research areas supported include virology, immunology, vaccine development and translational biomedical research. The portfolio includes reagents for the study of SARS-like coronaviruses, respiratory syncytial virus, human papillomavirus, Japanese encephalitis virus, rabies virus, monkeypox virus and other emerging pathogens. AntibodySystem collaborates with academic institutions, biotechnology companies, pharmaceutical organisations and research hospitals to support research and development activities.
The company offers a broad range of antibodies, proteins and assay reagents for therapeutic discovery and disease research. Product families include recombinant antibodies, therapeutic target proteins, biosimilar reagents and the Super-Affinity Bioreagents range. Its catalogue also features DNA and RNA antibodies, anti-PEG antibodies, phospho-specific antibodies, allergen antibodies, isotype controls and secondary antibodies. These reagents support workflows including biomarker research, target validation, immuno-oncology studies, antibody-drug conjugate development and bispecific antibody research. Products are available for targets such as PD-1, CTLA-8, TROP2 and CCR8, enabling investigation of immune regulation and therapeutic mechanisms.
Europa Biosite’s subsidiaries distribute for AntibodySystem in Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway, Sweden and Switzerland.